Table 1.
a. Age distribution of patients with newly coded CKD3a between 1/1/2015-31/12/2015, separated by the degree of albuminuria. CKD3aA1 = eGFR between 45-59mls/min/1.73m2 with uACR <3mg/mmol, CKD3aA2 = eGFR between 45-59mls/min/1.73m2 with uACR between 3-30mg/mmol and CKD3aA3 = eGFR between 45-59mls/min/1.73m2 with uACR >30mg/mmol. b. Ethnicity of patients with newly coded CKD3a between 1/1/2015-31/12/2015, separated by the degree of albuminuria. CKD3aA1 = eGFR between 45-59mls/min/1.73m2 with uACR <3mg/mmol, CKD3aA2 = eGFR between 45-59mls/min/1.73m2 with uACR between 3-30mg/mmol and CKD3aA3 = eGFR between 45-59mls/min/1.73m2 with uACR >30mg/mmol.
Table 2.
Comorbidities at baseline for each of the 3 study cohorts: CKD3aA1, CKD3aA2, and CKD3aA3.
CKD3aA1 = eGFR between 45-59mls/min/1.73m2 with uACR <3mg/mmol, CKD3aA2 = eGFR between 45-59mls/min/1.73m2 with uACR between 3-30mg/mmol and CKD3aA3 = eGFR between 45-59mls/min/1.73m2 with uACR >30mg/mmol.
Table 3.
Pearson’s Chi-squared test with Yates’ continuity correction, p values comparing co-morbidity occurrence according to degree of CKD at study baseline and end point within and between study groups.
Statistical significance = p <0.05. CKD3aA1 = eGFR between 45-59mls/min/1.73m2 with uACR <3mg/mmol, CKD3aA2 = eGFR between 45-59mls/min/1.73m2 with uACR between 3-30mg/mmol and CKD3aA3 = eGFR between 45-59mls/min/1.73m2 with uACR >30mg/mmol.
Fig 1.
Co-morbidities at baseline and endpoint for each of the 3 study cohorts: CKD3aA1, CKD3aA2, and CKD3aA3.
CKD3aA1 = eGFR between 45-59mls/min/1.73m2 with uACR <3mg/mmol, CKD3aA2 = eGFR between 45-59mls/min/1.73m2 with uACR between 3-30mg/mmol and CKD3aA3 = eGFR between 45-59mls/min/1.73m2 with uACR >30mg/mmol.
Fig 2.
Progression analysis of CKD3aA1/A2/A3 to CKD stage 5 over the 60-month follow-up period between January 2016-December 2021.
CKD3aA1 = eGFR between 45-59mls/min/1.73m2 with uACR <3mg/mmol, CKD3aA2 = eGFR between 45-59mls/min/1.73m2 with uACR between 3-30mg/mmol and CKD3aA3 = eGFR between 45-59mls/min/1.73m2 with uACR >30mg/mmol.
Table 4.
Prescription of RAASi and SGLT2i either singly or together in the last six months of the study period between 1/6/2021-31/12/2021.
CKD3aA1 = eGFR between 45-59mls/min/1.73m2 with uACR <3mg/mmol, CKD3aA2 = eGFR between 45-59mls/min/1.73m2 with uACR between 3-30mg/mmol and CKD3aA3 = eGFR between 45-59mls/min/1.73m2 with uACR >30mg/mmol. RAASi = Renin Angiotensin Aldosterone inhibitors. SGLT2i = Sodium-Glucose Cotransporter-2 Inhibitor.